Opportunities
We are developing new opportunities for our academic and clinical members, and building partnerships with patient, healthcare and industry partners. Our events , job opportunities and PhD studentships are regularly updated. We also offer occasional …
Patient partnerships
Our work is destined to have a direct impact on people living with heart attack and heart failure, their carers and families. These people have valuable lived experience that can help shape our research questions, approach and engagement. We recognise the …
Governance
The MRC/BHF CoRE in Advanced Cardiac Therapies began on 1 January 2025, with a duration of 14 years. Funding has been secured for an initial 7 year period. An experienced leadership team are responsible for delivering CoRE research and impact. Day-to-day …
Professor Eric Olson
Eric N. Olson PhD is the founding Chair of the Department of Molecular Biology at the University of Texas Southwestern Medical Center and founding chair of the Department of Molecular Biology at the University of Texas Southwestern Medical Center. He also …
Dr Martin Murphy
Martin Murphy is a life science investor. He was formerly co-founder and CEO of Syncona, and a director and founding investor of Autolus Therapeutics. He holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford. …
Dr Lauren Tedaldi
Lauren Tedaldi is Head of Research and Innovation Communications at Great Ormond Street Hospital for Children NHS Foundation Trust. Lauren has been a member of REACT's Independent Strategic Advisory Board since …
Amol Bhatnagar
Amol Bhatnagar is a civil engineer and person with lived experience of heart attack. Amol has been a member of REACT's Independent Strategic Advisory Board since …
Professor Sheila Francis
Sheila Francis is Professor of Cardiovascular Biology and Faculty of Health Director of One University Strategy Delivery at the University of Sheffield. Sheila has been a member of REACT's Independent Strategic Advisory Board since …
Dr Bill Haynes
Bill Haynes is Corporate Vice President of the Novo Nordisk Research Centre Oxford and Visiting Professor in Metabolic Medicine at the University of Oxford. Bill has been a member of REACT's Independent Strategic Advisory Board since …
Using lipid nanoparticles to deliver small RNAs to the heart
One of the bottlenecks for any application involving nucleic acid administration to the heart is efficiency of cardiac delivery. In the cases of both coding mRNA or RNA interference therapeutics (miRNAs, siRNAs), delivery needs to be facilitated in order …